Neuraxis, Inc. demonstrated solid revenue growth with a 32.9% increase to $3.57 million in FY2025, driven primarily by sales of its IB-Stim and RED devices that utilize proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company's competitive edge is supported by FDA clearance of PENFS treatment for functional abdominal pain, reinforced by a Category I CPT code assignment and inclusion in NASPGHAN pediatric guidelines, facilitating improved reimbursement and clinical adoption. Despite these commercial advances, Neuraxis continues to incur significant operating losses and negative cash flows reflecting ongoing research investments and commercialization costs. Key risks include regulatory scrutiny, intellectual property disputes, and reimbursement litigation which create near-term uncertainties. Growth prospects depend on expanded product indications, broader market penetration, and effective management of regulatory and legal challenges.